If mobile marketing isn't in your startup's toolkit, it should be. Photo via Getty Images

Consumer privacy is driving startups to immediately begin marketing and data collection. Google and Apple have recently stressed the importance of first-party data collection for businesses. For the last two decades, businesses have had access to cookies to advertise to people who visited their digital assets. Digital advertising has already changed with Apple’s iOS 14.5 alterations, switching the default of ad tracking from yes to no and both Google and Apple expect data privacy to increase.

For startups, when and how to begin marketing their business can feel like a cumbersome task. As a chief marketing officer, I was asked to list services and channels that I oversee, and I came up with 16. For founders of startups who must often take on the roles of CEO and COO in addition to CMO as they look to expand their teams, that time commitment is not reasonable for someone who also has a personal life.

Entrepreneurs need tools that are simple to institute and not cost prohibitive, to meet their respective milestones. First, we need to collect first party data, so that when we get to our minimum viable product we have plenty of people waiting to buy it. Next, marketing must work even when we can’t focus on it. Third, we must focus on revenue generating activities, whether they are marketing or not. Finally, we want to create an environment where successful entrepreneurs have a work and life balance.

Before doing anything else — get a virtual phone number

A virtual phone number is the first marketing tool I would use for any business. This number can be connected to your cell phone during certain hours of the day and disconnected for others. This allows people to reach you on your schedule. Put this phone number on every asset you have, so it can be integrated into future tools, such as customer relationship management and Google My Business. With proper opt-in information, it also creates an immediate list for SMS marketing in the future. A virtual phone number typically runs $1 to $2 a month plus usage fees, so it can be used by any business.

It is important that this is set up first, because without this, you can’t use the following marketing tools effectively.

Tool 1: Missed Call – Text Back

An entrepreneurs’ worst nightmare is missing an important phone call, whether it’s an investor or closing your first sale. Constant phone and email checking causes anxiety, but more importantly, it is a low revenue activity, so you are actively hurting your business.

Missed Call – Text Back, or MCTB, allows a customizable text message to be delivered to a client when you miss their phone call. It moves the caller towards resolution (sales or otherwise) immediately encouraging them to give you more information about their problem. The best part is, that once you have the system in place, it costs you zero time. Imagine walking out of a meeting and instead of 10 missed calls, you have 10 text messages that you can quickly answer. How much time did you just get back?

Pro Tip: In many cases, you can automate your emails in a similar way.

Tool 2: A funnel page

Now that we have a tool that allows us to work productively without constant phone checking, we need to increase our book of business. This is where a funnel comes in.

A funnel is a unique digital experience you would like a specific person — a client or investor — to have. When you start a business, a funnel can be your website because you only have one specific thing you want any visitor to do, like collect information.

Almost every consultant to new businesses is promoting funnel building. Why? Because a good funnel motivates people to act in a specific way. If you are raising funds, you want an investor to have a specific experience to garner interest, not hope they navigate to the correct webpage. If you have a new technology, you want early adopters to learn and then provide a simple way to collect their information, so that you can contact them when your product is ready. Finally, if you’re about to hit the market with your new product, providing customers with a simple purchase method will improve revenue during your important proof-of-concept period.

Funnels, like MCTB, can grow and adapt with your business, providing different groups of people with different experiences, with minimal effort. For instance, suppose I created a dating app and needed early adopters. Instead of creating one funnel, let’s say I created two. The only difference between the two funnels, is the first one’s headline was “The No. 1 new dating app for men” and then the second one said women. Everything else remains the same, but the experience is immediately different for the consumer. The more you can change the funnel to cater to their personal experience, the better it will be, but even simple changes can go a long way.

Pro Tip: Funnels are easiest to keep track of when they are subdomains of your website.

Tool 3: Automated SMS marketing

The final tool I recommend to start is Automated SMS Marketing. Assuming you have people properly opted in from your funnel — review Telephone Consumer Protection Act (1991) to ensure legal compliance — you can make sure they receive a welcome message in the first 5 minutes.

The most important part of text messaging marketing is allowing your customer to believe they are really having a conversation with you. If you can avoid it, never tell a customer that your digital number is automated. If you need, tell them it is automated but overseen by you. You are the owner of the business or the inventor of the technology, people want to talk to you. Customers want to pretend that they know you. Allow them this feeling. Once the customer responds, you should be picking up an organic conversation with them anyway.

Bringing it together

Using these tools, we have created a simple, repeatable method to gather customer data and start their customer journey. Your funnel may also help you gather an email list, but your most active prospects will be more than willing to communicate with you over the phone.

When you can’t take calls, whether it’s because you are in a meeting or with your kids, you can rest easier, knowing that potential customers get an immediate response that helps them get where they need to go, or at the very least, when you get back to work, you can help them quickly.

And the best part for a new entrepreneur is that this can all be done cost effectively. Personally, I recommend a service called HighLevel, a feature-rich cost-effective CRM, that includes all of the tools previously discussed. Most tech savvy entrepreneurs can figure out how to institute all these practices quickly from one platform in a no code environment. If you’d rather have assistance, there are 20,000 agencies that use the platform and just as many YouTube videos.

------

Chris Romani is the chief marketing officer for illumiPure, a Houston-based medical device company.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.